CanSino Biologics Inc. (CASBF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CanSino Biologics Inc. (CASBF). CanSino Biologics Inc. is a China-based biopharmaceutical company specializing in the development, manufacturing, and commercialization of innovative vaccines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026CanSino Biologics Inc. (CASBF) Healthcare & Pipeline Overview
CanSino Biologics Inc. is a Chinese vaccine company focused on developing and commercializing innovative vaccines, including its COVID-19 vaccine, Convidecia, and vaccines for other infectious diseases like Ebola and meningitis, positioning itself within China's growing biopharmaceutical market amidst competition from both domestic and international players.
Investment Thesis
CanSino Biologics presents a mixed investment case. Its COVID-19 vaccine, Convidecia, provided significant revenue during the pandemic, but future growth hinges on its pipeline of other vaccines. The company's high P/E ratio of 736.81 suggests that investors have high expectations for future earnings growth. CanSino's success depends on navigating regulatory approvals in China, successfully commercializing its pipeline products, and maintaining a competitive edge in the vaccine market. The company's ongoing research and development efforts, particularly in pneumococcal and tuberculosis vaccines, represent potential growth catalysts. However, the company faces competition from established global vaccine manufacturers and domestic players.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $1.35 billion indicates CanSino Biologics' current valuation in the market.
- A P/E ratio of 736.81 suggests that the company's stock price is high relative to its earnings.
- Gross margin of 100.0% reflects efficient vaccine production and sales.
- Profit margin of 2.6% indicates the percentage of revenue that turns into profit.
- Beta of 1.32 suggests the stock is more volatile than the market.
Competitors & Peers
Strengths
- Innovative vaccine technologies.
- Strong manufacturing capabilities.
- Established presence in the Chinese market.
- Successful development of COVID-19 vaccine.
Weaknesses
- High P/E ratio.
- Reliance on the Chinese market.
- Limited international presence.
- Dependence on regulatory approvals.
Catalysts
- Regulatory approvals for new vaccine candidates in China.
- Expansion of manufacturing capacity to meet growing demand.
- Progress in clinical trials for pneumococcal and tuberculosis vaccines.
- Potential partnerships with international organizations for global distribution.
- Continued research and development of innovative vaccine technologies.
Risks
- Competition from established vaccine manufacturers.
- Regulatory challenges and delays in approvals.
- Fluctuations in demand for vaccines.
- Patent expirations and intellectual property disputes.
- Dependence on the Chinese market.
Growth Opportunities
- Expansion of Vaccine Portfolio: CanSino has an opportunity to expand its vaccine portfolio beyond COVID-19. The development and commercialization of vaccines for diseases like pneumococcal disease (PBPV and PCV13i) and tuberculosis (TB Booster) can drive future revenue growth. The global pneumococcal vaccine market is projected to reach $12.9 billion by 2027, while the TB vaccine market is expected to grow as well, driven by the need for more effective TB prevention strategies.
- International Market Expansion: While currently focused on the Chinese market, CanSino can explore opportunities to expand its reach internationally, particularly in developing countries with unmet needs for vaccines. This expansion could involve partnerships with local distributors or establishing manufacturing facilities in other regions. The global vaccine market is expected to reach $90 billion by 2025, presenting significant opportunities for companies with innovative vaccine technologies.
- Development of Combination Vaccines: CanSino is developing combination vaccines like the DTcP-Hib Combo vaccine, which can provide protection against multiple diseases with a single injection. Combination vaccines can improve vaccination rates and reduce healthcare costs. The global market for combination vaccines is growing, driven by the convenience and cost-effectiveness of these products.
- Focus on Innovative Vaccine Technologies: CanSino's use of adenovirus vector technology for its COVID-19 vaccine demonstrates its commitment to innovation. The company can continue to invest in research and development of new vaccine technologies to improve vaccine efficacy, safety, and delivery. This includes exploring mRNA vaccine technology, which has shown promise in the development of COVID-19 vaccines.
- Partnerships and Collaborations: CanSino can leverage partnerships and collaborations with other pharmaceutical companies, research institutions, and government agencies to accelerate vaccine development and commercialization. These partnerships can provide access to new technologies, funding, and market expertise. Collaboration with international organizations like the WHO can also facilitate access to global markets.
Opportunities
- Expansion of vaccine portfolio.
- International market expansion.
- Development of combination vaccines.
- Partnerships and collaborations.
Threats
- Competition from established vaccine manufacturers.
- Regulatory challenges.
- Patent expirations.
- Fluctuations in demand for vaccines.
Competitive Advantages
- Proprietary vaccine technologies.
- Established manufacturing capabilities in China.
- Strong relationships with government agencies.
- First-mover advantage in certain vaccine markets in China.
About CASBF
CanSino Biologics Inc., founded in 2009 and headquartered in Tianjin, China, is a biopharmaceutical company dedicated to developing, manufacturing, and commercializing vaccines. The company's initial focus was on developing vaccines for prevalent infectious diseases. A key milestone was the development of Ad5-EBOV, an Ebola virus vaccine. CanSino gained prominence during the COVID-19 pandemic with its development of Convidecia, a single-dose COVID-19 vaccine. The company also produces MCV2 and MCV4 vaccines for the prevention of N. meningitides. CanSino continues to expand its pipeline with vaccines in various stages of development, including DTcP vaccines for infants, Tdcp Adolescent and Adult vaccines, and PBPV, a serotype-independent protein-based pneumococcal vaccine. The company is also engaged in preclinical research for vaccines targeting diseases such as adenovirus, ZIKA virus, meningitis, shingles, and polio. CanSino's geographic focus is primarily within China, aligning with the country's national health priorities and market demands.
What They Do
- Develops vaccines for infectious diseases.
- Manufactures vaccines in China.
- Commercializes vaccines in the Chinese market.
- Focuses on vaccines for COVID-19, Ebola, and meningitis.
- Conducts clinical trials for new vaccine candidates.
- Engages in preclinical research for future vaccines.
Business Model
- Develops proprietary vaccine technologies.
- Manufactures vaccines in its own facilities.
- Sells vaccines to government agencies and healthcare providers in China.
- Generates revenue through vaccine sales.
Industry Context
CanSino Biologics operates in the global vaccine market, which is characterized by increasing demand due to emerging infectious diseases and growing awareness of preventative healthcare. The market is dominated by established players like Pfizer and GSK, but also includes emerging companies like CanSino focusing on specific regional markets. The Chinese vaccine market is driven by government initiatives to improve public health and increase vaccine accessibility. The industry is subject to stringent regulatory requirements and requires significant investment in research and development.
Key Customers
- Government agencies responsible for public health.
- Hospitals and clinics.
- Vaccination centers.
- Individuals seeking vaccination.
CASBF Financials
CASBF Price Today & Live Chart
CanSino Biologics Inc. (CASBF) stock price: Price data unavailable
CASBF Latest News
No recent news available for CASBF.
CASBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CASBF.
Price Targets
Wall Street price target analysis for CASBF.
CASBF MoonshotScore
What does this score mean?
The MoonshotScore rates CASBF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Xuefeng Yu
CEO
Xuefeng Yu is the CEO of CanSino Biologics Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on vaccine development and commercialization. He has been instrumental in guiding CanSino through its growth phase, overseeing the development of key vaccine candidates and establishing partnerships with research institutions and government agencies. His leadership is focused on driving innovation and expanding CanSino's presence in the global vaccine market.
Track Record: Under Xuefeng Yu's leadership, CanSino Biologics has achieved significant milestones, including the development and approval of Convidecia, its COVID-19 vaccine. He has also overseen the expansion of CanSino's vaccine pipeline and the establishment of manufacturing facilities. His strategic decisions have positioned CanSino as a key player in the Chinese vaccine market.
CASBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CanSino Biologics may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB, or that it may be unwilling or unable to meet those standards. Companies on this tier may have limited financial disclosure, which increases the risk for investors. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, leading to less transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Financial Disclosure: The lack of transparency regarding CanSino Biologics' financial reporting makes it difficult for investors to assess the company's financial health and performance.
- Low Liquidity: The low trading volume associated with OTC Other stocks can make it challenging to buy or sell shares at desired prices.
- Regulatory Uncertainty: OTC Other companies are subject to fewer regulatory requirements than companies listed on major exchanges, which can increase the risk of fraud or mismanagement.
- Price Volatility: The limited liquidity and lack of information can lead to increased price volatility.
- Going Concern Risk: Companies on the OTC Other tier may face a higher risk of financial distress or bankruptcy.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the company's management team and their track record.
- Check for any regulatory actions or legal proceedings against the company.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Established vaccine development and manufacturing operations.
- Development and approval of COVID-19 vaccine.
- Partnerships with research institutions and government agencies.
- Focus on addressing public health needs in China.
What Investors Ask About CanSino Biologics Inc. (CASBF) — Healthcare
What does CanSino Biologics Inc. do?
CanSino Biologics Inc. is a biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of vaccines. The company's core focus is on developing innovative vaccines for a range of infectious diseases, including COVID-19, Ebola, and meningitis. CanSino leverages its proprietary vaccine technologies and manufacturing capabilities to produce and distribute vaccines primarily within the Chinese market, contributing to public health initiatives and disease prevention.
What do analysts say about CASBF stock?
Analyst coverage of CASBF stock is limited due to its OTC listing and focus on the Chinese market. However, key valuation metrics to consider include the company's high P/E ratio, which reflects investor expectations for future growth. Growth considerations revolve around the successful commercialization of its vaccine pipeline and expansion into international markets. Investors should monitor regulatory approvals and competitive dynamics in the Chinese vaccine market.
What are the main risks for CASBF?
The main risks for CanSino Biologics include competition from established global vaccine manufacturers, regulatory challenges and delays in obtaining approvals for new vaccines, and fluctuations in demand for its products. The company's reliance on the Chinese market also poses a risk, as changes in government policies or economic conditions could impact its business. Additionally, patent expirations and intellectual property disputes could threaten its competitive advantage.
What are the key factors to evaluate for CASBF?
Evaluating CASBF involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Innovative vaccine technologies. Primary risk to monitor: Competition from established vaccine manufacturers. This is not financial advice.
How frequently does CASBF data refresh on this page?
CASBF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CASBF's recent stock price performance?
Recent price movement in CanSino Biologics Inc. (CASBF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative vaccine technologies. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CASBF overvalued or undervalued right now?
Determining whether CanSino Biologics Inc. (CASBF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CASBF?
Before investing in CanSino Biologics Inc. (CASBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.